News
Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.
3don MSN
It will acquire genetic data of more than 15 million customers – raising privacy concerns from individuals who had willingly ...
Regeneron Pharmaceuticals is set to acquire substantially all assets of 23andMe for $256 million. The deal is expected to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results